Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × Oxaliplatin × Lymphoid × Clear all

Phase

Status

Sponsor Class

OTHER 30 INDUSTRY 27 NIH 5 UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10 Other solid neoplasm 1 Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1

Interventions

spartalizumab 2 Rituximab 2 tislelizumab 1 pegylated granulocyte colony-stimulating factor 1 pegaspargase 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Oxaliplatin 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Lenalidomide 1 Gemcitabine 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

ChineseAMS

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡